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In March 2014, the World Health Organization was notified of an outbreak of Zaire
ebolavirus in a remote area of Guinea. The outbreak then spread to the capital,
Conakry, and to neighboring countries and has subsequently become the largest
epidemic of Ebola virus disease (EVD) to date.
Methods

From March 25 to April 26, 2014, we performed a study of all patients with laboratoryconfirmed EVD in Conakry. Mortality was the primary outcome. Secondary outcomes included patient characteristics, complications, treatments, and comparisons
between survivors and nonsurvivors.
Results

Of 80 patients who presented with symptoms, 37 had laboratory-confirmed EVD.
Among confirmed cases, the median age was 38 years (interquartile range, 28 to 46),
24 patients (65%) were men, and 14 (38%) were health care workers; among the
health care workers, nosocomial transmission was implicated in 12 patients (32%).
Patients with confirmed EVD presented to the hospital a median of 5 days (interquartile range, 3 to 7) after the onset of symptoms, most commonly with fever (in
84% of the patients; mean temperature, 38.6°C), fatigue (in 65%), diarrhea (in 62%),
and tachycardia (mean heart rate, >93 beats per minute). Of these patients, 28 (76%)
were treated with intravenous fluids and 37 (100%) with antibiotics. Sixteen patients (43%) died, with a median time from symptom onset to death of 8 days (interquartile range, 7 to 11). Patients who were 40 years of age or older, as compared
with those under the age of 40 years, had a relative risk of death of 3.49 (95%
confidence interval, 1.42 to 8.59; P = 0.007).
Conclusions

Patients with EVD presented with evidence of dehydration associated with vomiting
and severe diarrhea. Despite attempts at volume repletion, antimicrobial therapy, and
limited laboratory services, the rate of death was 43%.
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E

bola virus is one of three members
of the Filoviridae family and comprises
five distinct species. Infection with Zaire
ebolavirus (EBOV) has historically resulted in the
highest case fatality rate — up to 90%.1 Outbreaks typically originate with introduction of
the virus into humans from a wild animal reservoir, with subsequent human-to-human transmission, often fueled by nosocomial amplification in resource-poor settings. Aside from a single
infection with Tai Forest ebolavirus, West Africa has
never had an outbreak of Ebola virus disease
(EVD).2,3
The Republic of Guinea, on the west coast of
Africa, has a population of approximately 11 million persons, a life expectancy at birth of 58 years,
and an annual gross national income of 970 international dollars, with an expenditure on health
care of 67 international dollars per capita per
year.4 Conakry, the capital and largest city, with
an approximate population of 2 million persons,
is served by a number of large hospitals, including
Donka Hospital (the major public and universityaffiliated medical center), Ignace Deen Hospital,
and the Hôpital de l’Amitié Sino-Guinéenne, in
addition to a number of privately funded health
clinics.
On March 21, 2014, the World Health Organization (WHO) was formally notified of a rapidly evolving outbreak of EVD centered in the
prefecture of Guéckédou, in the forested region
of southeastern Guinea, with potential spread
to border areas in Liberia and Sierra Leone.5
Infected travelers from Guéckédou subsequently initiated chains of transmission of EVD in
Conakry, more than 600 km away, marking the
world’s largest urban EVD outbreak and heralding the largest ever EVD epidemic, involving
Guinea, Sierra Leone, Liberia, Nigeria, Senegal,
and Mali.6 A concurrent but epidemiologically
unrelated outbreak has also been recognized in
the Democratic Republic of Congo.6
The care of patients with EVD in Conakry
initially occurred at two sites: the Hôpital de
l’Amitié Sino-Guinéenne, which mainly focused
on a large nosocomial outbreak affecting health
care workers, and a stand-alone EVD treatment
unit established on the grounds of Donka Hospital by the Ministry of Health, supported by
Médecins sans Frontières and the WHO. As of
October 31, 2014, the Guinea Ministry of Health
had reported a cumulative total of 1667 clinical
cases of EVD (with 1018 deaths), including 244
n engl j med 372;1

cases (and 98 deaths) in Conakry; a total of
13,562 cases (and 4950 deaths) were reported
throughout West Africa.7 Here we describe demographic and clinical characteristics of the
patients at presentation, the clinical course of
EVD, and outcomes of all patients admitted for
care in Conakry during a 1-month period at the
onset of the outbreak.

Me thods
Study Design

We conducted a retrospective, observational
study of all patients with suspected or confirmed
EVD who were admitted for care in Conakry
from March 25 to April 26, 2014 (Fig. S1 in the
Supplementary Appendix, available with the full
text of this article at NEJM.org). We used a standard case definition that was established by the
WHO and the Guinea Ministry of Health (Table
S1 in the Supplementary Appendix). Laboratory
confirmation of EVD was made on the basis of
results on quantitative reverse-transcriptase–
polymerase-chain-reaction (RT-PCR) assay in a
laboratory established at Donka Hospital by the
Institute Pasteur in Dakar, Senegal. Laboratory
staff members used rapid Taqman RT-PCR assays
for the detection of EBOV using 5-FAM and
3-TAMRA tagged probes and a portable SmartCycler TD. EBOV RNA in patient samples was
measured according to the standard described by
Weidmann et al.,8 in which the sample is diluted
to a range of 1 copy to 1 million copies and is
then tested in quadruplicate to construct a standard curve for estimating the number of genome
copies. Follow-up testing for antibodies against
EBOV by means of enzyme-linked immunosorbent assay (ELISA) was performed as needed. Patients were treated in accordance with protocols
established for viral hemorrhagic fever by Médecins sans Frontières and WHO urgent interim
guidance for case management, endorsed by the
Ministry of Health.9,10
Data Collection

Data-collection forms encompassed epidemiologic and demographic data, exposure history,
occupation and recent travel, symptoms, onset
date, vital signs at admission, and medical history. Also recorded were daily symptoms, vital
signs, complications, treatments, laboratory test
results when available, and outcomes. The clinical care team collected data from patients who

nejm.org

january 1, 2015

The New England Journal of Medicine
Downloaded from nejm.org at University of Nebraska Medical Center on December 3, 2021. For personal use only. No other uses without permission.
Copyright © 2015 Massachusetts Medical Society. All rights reserved.

41

The

n e w e ng l a n d j o u r na l

of

m e dic i n e

were admitted to EVD treatment units. Admission data were reviewed daily by clinicians. Approval and a waiver from the need to provide
written informed consent were obtained from
the ethics review committees for the Guinean
government and the WHO.

the clinically informed variables of age, sex, occupation, the presence of gastrointestinal hemorrhage, the number of days between symptom
onset and presentation, and viral load at presentation. We used Kaplan–Meier methods and logrank tests to determine survival curves for various groups of patients, using the interval from
Statistical Analysis
the onset of symptoms to death for those who
We used Student’s t-test, Fisher’s exact test, or died within 28 days, with data censored at 28
the Wilcoxon rank-sum test, as appropriate, to days for survivors. We explored associations bedetermine the association between mortality and tween the above-mentioned variables and death
in univariate analyses.
Table 1. Characteristics, Symptoms, Vital Signs, and Time Course of Clinical
We used a multivariate Poisson regression
Progression of 37 Patients with Confirmed Ebola Virus Disease (EVD).*
analysis with robust standard errors to investigate our three primary clinically informed hyVariable
Value
potheses: that mortality was associated with
Median age (IQR) — yr
38 (28–46)
older age, an increased interval from symptom
Male sex — no. (%)
24 (65)
onset until presentation to a treatment facility,
Health care worker — no. (%)
and an increased viral load.11,12 We examined
Yes
14 (38)
survival according to age using a scatter plot and
No
23 (62)
5-year age bins to determine the most appropriate dichotomous age comparisons. We logKnown mechanism of contact — no./total no. (%)†
transformed viral loads for primary compariHealth care
12/34 (35)
sons among survivors and nonsurvivors and
Household
23/37 (62)
performed sensitivity analyses dichotomizing
Funeral
6/37 (16)
viral loads using two sets of values (less than the
Known coexisting medical condition — no. (%)
sample median vs. greater than or equal to the
Hypertension
2 (5)
sample median and <100,000 copies per milliliter vs. ≥100,000 copies per milliliter). All statisHuman immunodeficiency virus
2 (5)
tical tests were two-tailed, with a P value of less
Diabetes
1 (3)
than 0.05 considered to indicate statistical sigRenal insufficiency
1 (3)
nificance. All analyses were performed with the
Tuberculosis
1 (3)
use of SAS software, version 9.3 (SAS Institute),
Malaria at presentation — no. (%)
4 (11)
and R software, version 2.15.1.
Symptoms — no./total no. (%)
Fever

31/37 (84)

Fatigue

24/37 (65)

Diarrhea

23/37 (62)

Headache

12/21 (57)

Vomiting

21/37 (57)

Anorexia

16/37 (43)

Vital signs at admission
Temperature — °C

38.6±1

Heart rate — beats/min

93±14

Systolic blood pressure — mm Hg

125±25

Median interval from onset of symptoms (IQR) — days
To hospital admission

5 (3–7)

To death

8 (7–11)

* Plus–minus values are means ±SD. IQR denotes interquartile range.
† Some patients had more than one exposure.
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R e sult s
Study Patients

Eighty patients who had symptoms meeting the
definition of suspected EVD were admitted to the
two treatment facilities in Conakry. Among these
patients, 37 (46%) were confirmed to have EVD,
36 (97%) by means of RT-PCR and 1 who had
negative results on RT-PCR assay but had positive
results for IgG antibodies on ELISA (Table 1).
The latter patient had a clinical syndrome compatible with EVD and was a close contact of another patient with confirmed disease.
The median age of the confirmed cases was
38 years (range, 19 to 61), and 24 (65%) were
men. The most common mechanism of contact
was through household clusters, which accounted for 23 cases (62%). Fourteen patients (38%)
nejm.org
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were health care workers, in whom nosocomial
transmission was implicated in 12 of 34 patients
(35%). Participation in funeral ceremonies of
confirmed cases was an additional risk factor
for 6 of these patients (16%).
Clinical features at presentation were nonspecific and included fever in 31 patients (84%;
mean temperature, 38.6°C), fatigue in 24 patients
(65%), gastrointestinal symptoms (in 23 patients
with diarrhea [62%] and 21 with vomiting
[57%]), headache in 12 of 21 patients who were
evaluated (57%), and anorexia in 16 patients
(43%) (Table 1). At admission, patients had mild
tachycardia (mean [±SD], 93±14 beats per minute) with a mean systolic blood pressure of
125±25 mm Hg. Hiccups occurred in 28% of
patients during the period of hospitalization.
The median time from symptom onset to presentation was 5 days (interquartile range, 3 to 7),
and the median time from symptom onset to
death was 8 days (interquartile range, 7 to 11).
Oral rehydration solution was given to 36 patients (97%), and 28 patients (76%) received additional intravenous fluid resuscitation (Table 2).
A median of 1 liter of intravenous crystalloids
was administered during the first 24 hours after
admission. Antibiotics were administered empirically in 37 patients (100%) with gastrointestinal
symptoms, and artemisinin-based combination
therapy was administered in 7 patients (19%), of
whom 4 had confirmed Plasmodium falciparum
infection on rapid diagnostic testing. One patient (3%) received supplemental oxygen therapy
for hypoxemia.
For the first 3 weeks of the outbreak, no routine clinical laboratory testing was available. For
approximately 1 week, we used an i-STAT System
point-of-care device with CHEM8+ and CG4+
cartridges (Abbott Point of Care) to perform limited diagnostic testing in 3 patients with clinical
symptoms in the treatment center. In 1 patient,
we found severe prerenal kidney dysfunction
(creatinine, 13.9 mg per deciliter [1229 μmol per
liter]; and blood urea nitrogen, >140 mg per deciliter [>50.0 mmol per liter]) and accompanying
metabolic acidosis (pH, 7.21; and lactate, 7.4 mmol
per liter), results that improved after the administration of approximately 5 liters of intravenous
crystalloid fluids per day for 3 days (creatinine,
2.4 mg per deciliter [212 μmol per liter]; blood
urea nitrogen, 40 mg per deciliter [14.3 mmol
per liter]; pH, 7.46; and lactate, 1.1 mmol per
n engl j med 372;1

liter). Similar findings were noted in a second
patient (creatinine, 4.9 mg per deciliter [433 μmol
per liter]; and blood urea nitrogen, 73 mg per
deciliter [26.1 mmol per liter]), findings that
were probably caused by profound diarrhea
(potassium, 2.4 mmol per liter; and bicarbonate,
15 mmol per liter), which also resolved after the
administration of approximately 4 liters of intravenous crystalloid fluids per day for 3 days
along with potassium. Among 3 patients in whom
anemia was suspected, including 1 patient with
clinical evidence of lower gastrointestinal bleeding, hematocrit levels were not profoundly low
(mean, 31.2±3.4).
Among the 16 patients (43%) who died, the
median duration of hospital stay was 5 days, as
compared with 9 days (interquartile range, 6 to
11) among survivors. The most common clinical
complication was hemorrhage, which was reported in 19 patients (51%), most frequently gastrointestinal bleeding (in 9 patients), of whom 8 patients had melena and 1 patient each had
hematemesis and hematochezia (Table 3).
In univariate analyses, the viral load appeared
to be higher among patients who died than in
survivors (Table 4), but this finding was influenced by the deaths of all 4 patients who had a
viral load of more than 100,000 copies per milliliter on admission, and viral load was not significantly associated with death on nonparametric
testing. Mortality was not significantly higher
among the few patients who had coexisting conditions than in those without such conditions
(57.1% vs. 40.0%, P = 0.44). However, an older
Table 2. Therapies Received by 37 Patients Hospitalized for EVD.
Therapy
Oral rehydration solution — no. (%)
Intravenous fluids — no. (%)
Median volume of crystalloid solution administered in first
24 hr (IQR) — liters

Value
36 (97)
28 (76)
  1 (1–1)

Antibiotic treatment — no. (%)
Any

37 (100)

Ciprofloxacin

20 (54)

Ceftriaxone

13 (35)

Cefixime

5 (14)

Amoxicillin–clavulanic acid

1 (3)

Antimalarial treatment — no. (%)

7 (19)

Supplemental oxygen therapy — no. (%)

1 (3)
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Value

Hospital mortality — no. (%)

16 (43)

Median length of stay in hospital (IQR) — days

8 (6–11)

m e dic i n e

(P = 0.007). There were no significant differences
between survivors and nonsurvivors in the number of days between symptom onset and admission (relative risk in survivors, 0.94; 95% CI, 0.86
to 1.04; P = 0.22) and viral load on admission
(relative risk, 0.98; 95% CI, 0.91 to 1.07; P = 0.72).

Table 3. Clinical Complications and Outcomes for 37 Patients with EVD.
Variable

of

Known complications in hospital — no. (%)
Hemorrhage
Any

Discussion

19 (51)

Gastrointestinal

9 (24)

Subconjunctival

4 (11)

Intravenous catheter site

4 (11)

Nasorespiratory tract

2 (5)

Renal failure*

2 (5)

Seizure

2 (5)

Oral candidiasis

1 (3)

Hypoxemia

1 (3)

* Renal failure was defined as a serum creatinine level of more than 4 mg per
deciliter (350 μmol per liter).

age was associated with an increased risk of
death, with a median age of 29 years in survivors
as compared with 45 years in those who died
(P = 0.005) (Fig. 1). In a multivariable Poisson
regression analysis that was adjusted for age,
viral load, and time from symptom onset to
presentation, patients who were 40 years of age
or older had a relative risk of death of 3.49 (95%
confidence interval [CI], 1.42 to 8.59), as compared with those under the age of 40 years

Patients, on average, presented 5 days after
symptom onset, and the most common manifestations of EVD during hospitalization were fever,
vomiting, diarrhea, and related volume depletion
requiring the administration of intravenous fluids and electrolyte therapy. Overall mortality
among patients presenting for treatment was
43%, and only the age of the patient was a significant predictor of outcome. In contrast to previous Ebola virus outbreaks in which an older age
was also associated with a worse outcome, the
mean age of nonsurvivors in our study was
low.13,14 The association between an older age
and a worse outcome among patients with viral
infections is often attributed to an increased
number of coexisting conditions. However, in
our study, the relative absence of known coexisting conditions suggests that an older age may
have an independent association with mortality.
We also found that patients who presented for
care with the highest viral loads were the least
likely to survive, as has been shown for other
strains of Ebola virus.15 After adjustment for dif-

Table 4. Characteristics of Survivors and Nonsurvivors.
Characteristic

Survivors
(N = 21)

Nonsurvivors
(N = 16)

P Value

Median age (IQR) — yr

29 (26–37)

45 (40–47)

0.005

14:7

10:6

1.00

8207±17,189

68,361±111,340

0.02

1079 (148–5059)

1915 (141–12,998)

0.47

0

4 (25)

0.02

6 (29)

8 (50)

0.31

Any visible

8 (38)

11 (69)

0.1

Gastrointestinal

4 (19)

6 (38)

1.0

5 (4–8)

5 (2–7)

0.49

Male:female ratio
Viral load at admission
Mean ±SD — copies/ml
Median (IQR) — copies/ml
>100,000 copies/ml — no. (%)
Health care worker — no. (%)
Clinical features
Hemorrhage — no. (%)

Interval from symptom onset to presentation (IQR) —
days
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1.0

Age <40 yr

0.8

Probability of Survival

ferences in age and time to presentation, this
relationship was not significant. However, our
study had limited power to detect all predictors
of outcome because of the small number of patients.
The case fatality rate that we observed in this
cohort in the capital city of Conakry was lower
than the rate reported in most studies of previous EVD outbreaks1 (although not in all studies7) and was lower than the rate in most other
regions in Guinea at that point in the epidemic.7,13 Clinical care at the main isolation facility
near Donka Hospital was jointly provided by the
Ministry of Heath, Médecins sans Frontières,
and the WHO during the study period. Adherence to new guidelines promoting increased
medical interventions, particularly related to the
use of oral and intravenous fluids and electrolyte
replacement, appropriate antibiotics, and targeted
clinical laboratory testing,9 may have contributed to the reduced case fatality rate, as compared
with past outbreaks. However, assessing associations between treatments and outcomes in small
observational studies is challenging. In our
study, there were approximately three clinical
rounds per day, with two or three doctors and
two or three nurses for each round, and depending on the type of personal protective equipment
that was used, rounds were limited to either 1 hour
or 3 hours because of the intense heat and humidity inside some types of personal protective
equipment. Although we attempted to deliver
oral and intravenous fluids to correct dehydration and metabolic abnormalities, care was still
suboptimal. With more clinical personnel in each
treatment center, better supportive care could be
delivered more consistently, and we think that
mortality could be driven lower.
The predominant clinical syndrome of EVD
involves substantial volume loss due to vomiting
and diarrhea. This requires aggressive oral and
intravenous volume repletion and close followup to avoid further complications and hypoperfusion-associated organ dysfunction. Point-of-care
diagnostic testing provided additional insights
in a small number of patients, suggesting inadequate tissue perfusion — lactic acidosis, base
deficits, prerenal kidney dysfunction, and low
venous oxygen saturations. However, we could
not perform such testing early or frequently
enough to properly define the patterns. The substantial volume loss and profound electrolyte

0.6

Overall

0.4
Age ≥40 yr
0.2
P=0.002 by log-rank test
0.0

0

7

14

21

28

Days since Onset of Symptoms
No. at Risk
Age <40 yr
Age ≥40 yr

19
15

18
12

15
6

15
4

15
4

Figure 1. Kaplan–Meier Estimate of the Probability of Survival among Patients
with Ebola Virus Disease, According to Age.

derangement from copious diarrhea represent
opportunities to intervene clinically to improve
outcomes. Notably, hypoxemia was rarely seen
in these patients, despite attempts at aggressive
volume repletion. However, this finding may still
represent inadequate volume administration, and
hypoxemia caused by pulmonary vascular leak
may be more common in other care settings.
Consideration may also be given to the empirical
use of antimalarial therapy, especially if rapid
diagnostic testing is not immediately available.
Patients with severe gastrointestinal symptoms
were also routinely treated with a finite empirical course of antibiotics with activity against
gram-negative, gram-positive, and anaerobic organisms. However, the effect of this intervention
remains unknown.
As has been seen in other disease outbreaks,
but never before with EVD, large urban settings
present special challenges to emergency health
care facilities, and nosocomial transmission
among health care staff members and patients
represents an important potential outbreak amplification and new lines of transmission.16,17
This finding highlights the importance of rapid
support for infection control, not only in dedicated isolation facilities but also within existing
treatment centers that will typically receive un-
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differentiated patients with fever and nonspecific symptoms. Infection-control practices to
protect patients and health care workers can
have unanticipated negative consequences, including fewer clinical assessments, which may
be compounded by limited clinician time at the
bedside because of heat exposure in personal
protective equipment.18,19
Limitations of our study include reliance on
estimates from a discrete but relatively small
cohort of patients. However, the observed mortality in Conakry (43%) has remained relatively
stable (40%) between April and October 2014.20
Despite an active public health system for tracing contacts, case finding, and referral to an
acute care facility, we inevitably are unable to
identify all patients with suspected and confirmed EVD, since some will choose not to pre
sent to health care facilities and some will die
before seeking medical attention. This potential
selection bias will underestimate the number of
cases and have uncertain effects on the case fatality rate for this epidemic. The inclusion of
only patients who could be transported to our
health care facilities may lead to a survivorship
and immortal time bias, since patients with EVD
needed to have survived long enough to get to a
facility in order to be described and to receive
certain treatments. Furthermore, selection of
patients for certain treatments is subject to bias
according to indication, which can lead to an
overestimation of harm for certain therapies.21
Therefore, in this observational study, we are
unable to validly explore relationships between

of

m e dic i n e

treatments received and clinical outcomes,
which underscores the importance of enhanced
strategies for supportive care and specific therapies in future clinical trials.
Our recording of simple clinical data was also
limited by an inability to take any material, including paper, outside the treatment center, by
limited electricity to power onsite electronic data
capture, and by unreliable Internet access. Inside
the treatment facility, with too few clinical staff
members, there is often a trade-off between delivering and recording care. A further limitation
is the paucity of basic data regarding blood chemistry and hematology that would better characterize metabolic abnormalities and help to direct
care for future patients. Point-of-care testing
inside treatment centers is challenging because
of a lack of time to perform testing due to high
temperatures and dehydration of health care
providers. Routine deployment of basic chemistry and hematology analyzers in addition to RTPCR assays for EBOV in international mobile
laboratories would alleviate this limitation and
may guide further improvements in patient care.
In conclusion, we found that among patients
admitted to the hospital with confirmed EVD in
Conakry, Guinea, the most common clinical
syndrome was one of gastrointestinal illness,
intravascular volume depletion, and related complications, which highlight the importance of
enhanced levels of clinical assessment and diagnostic testing, along with fluid management.
Disclosure forms provided by the authors are available with
the full text of this article at NEJM.org.
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